Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request

1. AstraZeneca requested the European Medicines Agency (EMA) to temporarily suspend the marketing authorization of its COVID-19 vaccine, Vaxzevria, in Europe.
2. The suspension is a precautionary measure while the EMA conducts a review of the vaccine's safety and effectiveness.
3. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) will evaluate the available data and determine if any changes are needed in the vaccine's authorization.
4. The suspension does not mean that the vaccine has been found to be unsafe or ineffective, but rather that further review is needed to ensure its continued safety and efficacy.
5. The decision to suspend the marketing authorization was made in the interest of public health and to ensure the continued trust in COVID-19 vaccines.
6. The EMA will provide updates on the review process and any changes to the vaccine's authorization status.
7. The suspension applies only to the Vaxzevria vaccine and does not affect other COVID-19 vaccines authorized for use in Europe.
8. AstraZeneca has stated that it remains committed to working with the EMA and other regulatory authorities to ensure the safety and efficacy of its COVID-19 vaccine.